An end-to-end automated platform process for high-throughput engineering of next-generation multi-specific antibody therapeutics.
Furtmann N, Schneider M, Spindler N, Steinmann B, Li Z, Focken I, Meyer J, Dimova D, Kroll K, Leuschner WD, Debeaumont A, Mathieu M, Lange C, Dittrich W, Kruip J, Schmidt T, Birkenfeld J.
Furtmann N, et al. Among authors: li z.
MAbs. 2021 Jan-Dec;13(1):1955433. doi: 10.1080/19420862.2021.1955433.
MAbs. 2021.
PMID: 34382900
Free PMC article.